Levera XR 500 Tablet contains Levetiracetam 500 mg, an antiepileptic medication indicated for the treatment of partial-onset seizures, myoclonic seizures, and primary generalized tonic-clonic seizures in patients with epilepsy. Levetiracetam acts by modulating synaptic neurotransmitter release through binding to the synaptic vesicle protein SV2A, thereby reducing neuronal excitability and seizure activity. Levera XR 500 is formulated as an extended-release tablet to provide a sustained therapeutic effect, allowing for once-daily dosing which may improve patient adherence. It is typically prescribed as adjunctive therapy in adults and pediatric patients aged 4 years and above. The dosage should be individualized based on clinical response and tolerability, with careful titration to minimize adverse effects. Common side effects include somnolence, dizziness, fatigue, and headache, which are generally mild to moderate in severity. Caution is advised in patients with renal impairment, and dose adjustments may be necessary. Levera XR 500 should be used under strict medical supervision, with regular monitoring for efficacy and safety. Patients are advised not to discontinue therapy abruptly to avoid increased seizure risk. This medication is contraindicated in individuals with known hypersensitivity to Levetiracetam or any of its excipients.